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In many parts of the world, numerous outbreaks of pertussis have been described despite
high  vaccination coverage. In this article we report the epidemiological characteristics of
pertussis in Brazil using a Surveillance Worksheet. Secondary data of pertussis case inves-
tigations reported from January 1999 to December 2008 recorded in the Information System
for  Notiﬁable Diseases (SINAN) and the Central Laboratory for Public Health (LACEN-MS)
were  utilized. The total of 561 suspected cases were reported and 238 (42.4%) of these were
conﬁrmed,  mainly in children under six months (61.8%) and with incomplete immuniza-
tion  (56.3%). Two outbreaks were detected. Mortality rate ranged from 2.56% to 11.11%. The
occurrence of outbreaks and the poor performance of cultures for conﬁrming diagnosis areordetella  pertussis
utbreak investigation
problems  which need to be addressed. High vaccination coverage is certainly a good strategy
to  reduce the number of cases and to reduce the impact of the disease in children younger
than  six months.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDntroduction
ertussis is an acute infection of the respiratory tract with
 growing number of people at risk of contracting the dis-
1ase  in many  parts of the world. Even after the decrease in
revalence  following the advent of the Diphtheria, Tetanus,
ertussis (DTP) vaccine, pertussis has remained a signiﬁ-
ant  public health problem. Globally, an estimated overall
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Este é um artigo Open Access sob a licençaannual incidence of 50 million cases, 95% of them in
developing countries,1 and approximately 300,000 deaths
have  been caused by this disease, with a mortality rate of
around  1% in developing countries and 0.04% in developed
countries.2
In many  parts of the world, numerous outbreaks of pertus- Lourenc¸o,  CEP 79041-310 Campo Grande, MS, Brazil.
sis  have been described despite high vaccination coverage.3–5
In this article, we report the epidemiological characteristics of
pertussis  in the state of Mato Grosso do Sul, Brazil.
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Fig. 1 – Reported and conﬁrmed pertussis cases and
percentage of vaccine coverage, Mato  Grosso do Sul,178  b r a z j i n f e c t d 
Materials  and  methods
This descriptive, cross-sectional and retrospective study
included  all Pertussis Surveillance Worksheet used from Jan-
uary  1999 to December 2008 to report pertussis suspected
cases to the Health Department of the State of Mato Grosso
do  Sul, Brazil. The data were  collected from worksheets after
local  institutional review board approval.
The Brazilian vaccination scheme against Bordetella pertus-
sis  is composed by three doses at two, four and six months
with  the ﬁrst booster at 6 to 12 months after the third dose
and  second booster at four to six years.6
It was  used the terms established by the Brazilian Min-
istry  of Health6 for the case deﬁnition. Suspected case – every
individual  presenting dry cough for 14 days or more  associ-
ated  with one or more  of the following symptoms: paroxysmal
cough  – sudden uncontrollable cough, with 5–10 quick and
short  coughs in a single exhalation; inspiratory whoop, post-
cough  vomiting; or having a history of contact with a pertussis
case  conﬁrmed by clinical criteria.
Conﬁrmed case: (a) by laboratorial criteria: isolation of
Bordetella  pertussis; (b) by epidemiological criteria: any sus-
pected  case which has had contact with a pertussis conﬁrmed
case  by laboratory testing, between the beginning of the
catarrhal  period up to three weeks after onset of the
disease paroxysmal period; (c) by clinical criteria: every sus-
pected  case of pertussis whose hemogram shows leukocytosis
(over  20,000 leukocytes/mm3) and absolute lymphocytosis
(over 10,000 leukocytes/mm3) and negative or not performed
culture; and absence of epidemiological linkage; and no con-
ﬁrmation  of another etiology.
Excluded  case: any suspected case that does not conform
to  any of the previously described criteria for conﬁrmed cases.
The  incidence rate was  calculated based on the population
estimated by the Brazilian Institute of Geography and Statis-
tics  (IBGE) during the study period. Statistical analyses were
performed  using the program Epi Info 3.5.1.
This study was  approved by the Federal University of Mato
Grosso  do Sul Research Ethics Committee, under protocol no.
1147.
Results
During the 10 years of the study period, the average of per-
tussis  incidence in Mato Grosso do Sul was  1.07 cases/100,000
population and the average of vaccine coverage was  81.48%.
The  vaccine used in Brazil is the whole-cell pertussis vaccine
(WCVs).
Of  the 561 pertussis suspected cases that were reported
to  the Health Department of the State of Mato Grosso do
Sul  – Brazil, 238 (42.4%) were  conﬁrmed and 281 (50.1%) were
excluded.  No classiﬁcation was  deﬁned in the worksheet of 42
(7.5%)  cases and these cases were not considered as conﬁrmed
or  excluded.
Considering the conﬁrmed cases, 132 (55.5%) were female
and  106 (44.5%) were  male. The highest incidence of cases
(61.8%)  occurred between zero to six months of age (Table 1).
Among  infected children, contagion occurred in 134 (56.3%)
cases  before the patient had reached the age recommended1999–2008.
for the initiation of the vaccination scheme or showed incom-
plete  immunization (up to two doses). Fig. 1 demonstrates the
distribution  of reported and conﬁrmed pertussis cases during
the  study period and the percentage of vaccine coverage in the
state.
Regarding  the diagnostic conﬁrmation criteria, 7.6%
(18/238) of the pertussis cases were conﬁrmed by laboratory
testing (positive culture), 22.7% (n = 54/238) by epidemiologic
linkage (suggestive clinical proﬁle and contact with conﬁrmed
case),  68.1% (162/238) by clinical criteria (suggestive clinical
proﬁle  associated with leukocytosis and lymphocytosis) and
the  conﬁrmation criteria was not included in the Pertussis
Surveillance Worksheet of 1.7% (n = 4/238) cases. Nasopharyn-
geal  secretion culture was  collected of 61 conﬁrmed cases
patients  and 18 (29.5%) of these cultures were  positive.
Two  pertussis outbreaks were observed in the state in 2004
and  2007. Fifty cases were reported during the ﬁrst outbreak
and  11 (22%) were conﬁrmed while 68 cases were  reported dur-
ing  the second outbreak and 12 (17%) cases were conﬁrmed.
No  pertussis-related deaths occurred during the outbreaks.
Five  deaths occurred among the conﬁrmed cases and
patients age ranged from 18 days to three years. The case
fatality  ratio over the whole 10-year period was  4.9% (4/82) in
children up to two months and 0.9% (1/108) in children older
than  two months. Only one child was diagnosed by positive
Bordetella pertussis culture; the others were conﬁrmed by clini-
cal  criteria. The highest mortality rate of 11.11% was  recorded
in  2000. In the years 1999, 2002 and 2008, mortality rates were
5.56%,  4.46% and 2.56%, respectively.
Discussion
Bordetella pertussis infection remains a serious problem to
children  not immunized or with incomplete immunization.
In  Porto Alegre, 54% of children with pertussis had incomplete
vaccination schedule with only 0–2 vaccine doses having been
adminstered.7 The infection in these population suggests
that  adults who have lost their vaccinal immunity can be
important  sources of infection.3,6The higher incidence of pertussis in children up to six
months has been also described by other Brazilian authors.7,8
In Recife,8 72.5% of pertussis cases were found to occur in
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Table 1 – Number of vaccine doses by age group of pertussis cases, Mato Grosso do Sul – Brazil, from 1999 to 2008.
Age group N/% Number of doses
0 1 2 3 4 or more NR
Up to 2 m 82/34.5 54  15 0 0 0 13
3–6 m 65/27.3 15  21 14 1 0 14
7–11 m 10/4.2 1 1 3 2 0 3
1–4 y 33/13.9 2 4 1 9 11 6
5–9 y 28/11.8 2 0 0 1 20 5
10–14 y 10/4.2 0 1 0 0 6 3
15 y or more 10/4.2 0 0 0 0 4 6
Total 238/100 74/31.1 42/17.6 18/7.6 13/5.5 41/17.2 50/21
c
6
t
h
r
d
e
t
t
c
O
o
o
c
w
s
d
a
e
I
2
p
c
i
o
w
u
p
w
o
t
o
(
c
f
m
p
t
t
a
uma  nova estratégia vacinal. Rev Port Pneumol.
2010;16:573–88.Note: m, months; y, years; NR, not reported.
hildren younger than six months of age and in Porto Alegre
7.0%  of children with pertussis were  observed to be younger
han  one year.7
The USA pertussis incidence is lower than 1.0%. The
igh  vaccination coverage in children by age two years has
esulted  in historically low levels of most vaccine-preventable
iseases in the United States. The estimated vaccination cov-
rage  among children aged 19–35 months ranged from 95.0%
o  96.2% according to the National Immunization Survey of
he  United States, 2007–2011.9 In Europe, the vaccination
overage ranged from 90.0% in France to 100.0% in Sweden.10
n the other side, since 2012 United Kingdom faces outbreak
f  pertussis in unimmunized young children with high rates
f  morbidity and mortality.5
The majority of pertussis cases were identiﬁed by clinical
riteria. These data are similar to another study in the country,
here  51% of the cases were  conﬁrmed by clinical criteria,
uch  as clinical proﬁle (26%) and suggestive WBC.11
Culture is considered the gold standard for pertussis
iagnosis and the only criteria for laboratory conﬁrmation
ccepted by the Brazilian Ministry of Health.6,12 Among differ-
nt  studies, positivity of cultures varied from 9.4% to 78%.4,8
n our study, nasopharyngeal secretion was  collected in just
5.6%  (61/238). The culture of nasopharyngeal secretion was
ositive  in 29.5% (18/61) of these cases, highlighting the difﬁ-
ulty  in obtaining a deﬁnitive diagnosis. Culture sensitivity is
nﬂuenced by several factors, including the fastidious nature
f  B. pertussis, the stage of the disease at which the collection
as  made, the vaccination status of the individual, the prior
se  of antibiotics and transport conditions of the samples.12
The geographical distance and the logistics of sending sam-
les  from the collection site to the laboratory where cultures
ere  processed may  also have interfered in the low percentage
f  positive results, since there was  a single reference labora-
ory  to perform all cultures in the state. Performing culture
n  all of the suspected cases and Polymerase Chain Reaction
PCR)  technique PCR would also add to the identiﬁcation of
ases.  Moreover, the state does not have a laboratory to per-
orm  the PCR for B. pertussis detection. PCR was  adopted by
any  countries to aid in laboratory diagnosis and improve
ertusssis surveillance.11,13
The outbreaks observed in 2004 and 2007 occurred in
he  period in which children vaccination coverage was less
han  90% in the State while Brazilian rates have remained at
pproximately 80% for children aged 1–12.14 The improvementof the epidemiological surveillance system may  also explain
the  detection of the outbreaks.
Of  the ﬁve reported deaths, similar to the result of other
study,  all of them occurred in children and the majority of
them  were  younger than two months of age. The high mor-
bidity  as well as severity, increased risk of complications and
mortality  in children younger than six months are recognized
factors  involved in pertussis.15 The detection of pertussis over
a  period of 10 years and the evidence of two outbreaks demon-
strate  that disease is an important public health problem and
there  is an evident risk of infection to children under six
months.  It is also possible to have the suspected cases go
underreported.
The  difﬁculty of diagnosing pertussis by laboratory meth-
ods  seems to collaborate to turn this into a neglected disease
in  the state. The implementation of new diagnostic methods,
such  as molecular biology techniques, could improve these
results.  In the same way, high vaccination coverage is certainly
a  good strategy to reduce the number of cases and to reduce
the  impact of the disease in children younger than six months.
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